Recursion Pharmaceuticals (NASDAQ: RXRX) was in the headlines on Monday, and for the right reason. One of the biotech company's investigational drugs did well in a clinical trial, and investors ...
Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. The company raised over $500 million in its IPO, making it the sixth-largest ...
Hosted on MSN
Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025
We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results